Kiromic Biopharma Inc (NASDAQ:KRBP) — Market Cap & Net Worth
Market Cap & Net Worth: Kiromic Biopharma Inc (KRBP)
Kiromic Biopharma Inc (NASDAQ:KRBP) has a market capitalization of $214.93K ($214.93K) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31318 globally and #6317 in its home market, demonstrating a 1.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kiromic Biopharma Inc's stock price $22.96 by its total outstanding shares 2653480 (2.65 Million). Also see Kiromic Biopharma Inc assets under control for a full breakdown of the balance sheet.
Kiromic Biopharma Inc Market Cap History: 2020 to 2026
Kiromic Biopharma Inc's market capitalization history from 2020 to 2026. Data shows change from $674.25 Million to $60.92 Million (-36.75% CAGR). Also see cash flow conversion of Kiromic Biopharma Inc for how efficiently the company converts equity into cash flow.
Kiromic Biopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kiromic Biopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Kiromic Biopharma Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KRBP by Market Capitalization
Companies near Kiromic Biopharma Inc in the global market cap rankings as of September 18, 2026. Review how tangible is Kiromic Biopharma Inc's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kiromic Biopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Kiromic Biopharma Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Kiromic Biopharma Inc's market cap moved from $674.25 Million to $ 60.92 Million, with a yearly change of -36.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $60.92 Million | +56866.50% |
| 2025 | $106.94K | -95.52% |
| 2024 | $2.39 Million | +3.45% |
| 2023 | $2.31 Million | -83.95% |
| 2022 | $14.38 Million | -88.34% |
| 2021 | $123.39 Million | -81.70% |
| 2020 | $674.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Kiromic Biopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $214.93K USD |
| MoneyControl | $214.93K USD |
| MarketWatch | $214.93K USD |
| marketcap.company | $214.93K USD |
| Reuters | $214.93K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more